Guidant Clarifies J&J Merger Terms, Incentives For Execs, Antitrust Defense

Antitrust regulators weighing the potential impact of a J&J/Guidant merger on the DES market are likely to be mollified by the number of firms with drug-eluting stents in development, Guidant CEO Ron Dollens says

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight